<DOC>
	<DOC>NCT00282464</DOC>
	<brief_summary>This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed. Subjects are required to undergo a washout period of at least 7 days of any prior med.</brief_summary>
	<brief_title>A Six-Week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Subjects must have a primary diagnosis of Bipolar I Disorder, most recent episode depressed, with or without rapid cycling, without psychotic features, as defined in DSMIVTR (296.5X) and confirmed by a structured Mini International Neuropsychiatric Interview (MINI) Subjects with a DSMIV TR diagnosis of schizophrenia (295.XX), schizoaffective disorder (295.70), schizophreniform disorder (295.40), delusional disorder (297.1), or psychotic disorder NOS (298.9). Subjects with other DSMIV TR Axis I or Axis II disorder (in addition to Bipolar I disorder) are ineligible if the comorbid condition is clinically unstable, requires treatment, or has been a primary focus of treatment within the 6 month period prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Bipolar I Depression</keyword>
</DOC>